Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 1
1980 1
1982 1
1987 4
1988 2
1990 4
1991 8
1992 2
1993 6
1994 2
1996 1
1997 1
1998 2
2000 3
2001 1
2002 5
2003 2
2004 1
2005 1
2006 2
2008 4
2009 5
2010 2
2011 4
2012 2
2013 5
2014 5
2015 5
2016 11
2017 13
2018 4
2019 4
2020 3
2021 4
2022 10
2023 5
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Results by year

Filters applied: . Clear all
Page 1
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators. Hochhaus A, et al. N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324. N Engl J Med. 2017. PMID: 28273028 Free PMC article. Clinical Trial.
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM; ENESTnd Investigators. Saglio G, et al. N Engl J Med. 2010 Jun 17;362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5. N Engl J Med. 2010. PMID: 20525993 Free article. Clinical Trial.
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H; PACE Investigators. Cortes JE, et al. N Engl J Med. 2013 Nov 7;369(19):1783-96. doi: 10.1056/NEJMoa1306494. Epub 2013 Nov 1. N Engl J Med. 2013. PMID: 24180494 Free PMC article. Clinical Trial.
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Strömberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machová Poláková K, Müller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX; EURO-SKI investigators. Saussele S, et al. Lancet Oncol. 2018 Jun;19(6):747-757. doi: 10.1016/S1470-2045(18)30192-X. Epub 2018 May 4. Lancet Oncol. 2018. PMID: 29735299 Clinical Trial.
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.
Mahon FX, Pfirrmann M, Dulucq S, Hochhaus A, Panayiotidis P, Almeida A, Mayer J, Hjorth-Hansen H, Janssen JJWM, Mustjoki S, Martinez-Lopez J, Vestergaard H, Ehrencrona H, Machová Poláková K, Olsson-Strömberg U, Ossenkoppele G, Berger MG, Etienne G, Dengler J, Brümmendorf TH, Burchert A, Réa D, Rousselot P, Nicolini FE, Hofmann WK, Richter J, Saussele S; EURO-SKI Investigators; Investigators. Mahon FX, et al. J Clin Oncol. 2024 Jun 1;42(16):1875-1880. doi: 10.1200/JCO.23.01647. Epub 2024 Mar 12. J Clin Oncol. 2024. PMID: 38471049
Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option.
Dolinska M, Cai H, Månsson A, Shen J, Xiao P, Bouderlique T, Li X, Leonard E, Chang M, Gao Y, Medina JP, Kondo M, Sandhow L, Johansson AS, Deneberg S, Söderlund S, Jädersten M, Ungerstedt J, Tobiasson M, Östman A, Mustjoki S, Stenke L, Le Blanc K, Hellström-Lindberg E, Lehmann S, Ekblom M, Olsson-Strömberg U, Sigvardsson M, Qian H. Dolinska M, et al. Among authors: stenke l. Blood. 2023 Jul 6;142(1):73-89. doi: 10.1182/blood.2022016896. Blood. 2023. PMID: 37018663 Free PMC article.
132 results